TY - JOUR
T1 - Dendritic cell immunotherapy
T2 - clinical outcomes
AU - Apostolopoulos, Vasso
AU - Pietersz, Geoffrey A.
AU - Tsibanis, Anastasios
AU - Tsikkinis, Annivas
AU - Stojanovska, Lily
AU - McKenzie, Ian F.C.
AU - Vassilaros, Stamatis
N1 - Publisher Copyright:
© 2014 The Authors
PY - 2014/7/1
Y1 - 2014/7/1
N2 - The use of tumour-associated antigens for cancer immunotherapy studies is exacerbated by tolerance to these self-antigens. Tolerance may be broken by using ex vivo monocyte-derived dendritic cells (DCs) pulsed with self-antigens. Targeting tumour-associated antigens directly to DCs in vivo is an alternative and simpler strategy. The identification of cell surface receptors on DCs, and targeting antigens to DC receptors, has become a popular approach for inducing effective immune responses against cancer antigens. Many years ago, we demonstrated that targeting the mannose receptor on macrophages using the carbohydrate mannan to DCs led to appropriate immune responses and tumour protection in animal models. We conducted Phase I, I/II and II, clinical trials demonstrating the effectiveness of oxidised mannan-MUC1 in patients with adenocarcinomas. Here we summarise DC targeting approaches and their efficacy in human clinical trials.
AB - The use of tumour-associated antigens for cancer immunotherapy studies is exacerbated by tolerance to these self-antigens. Tolerance may be broken by using ex vivo monocyte-derived dendritic cells (DCs) pulsed with self-antigens. Targeting tumour-associated antigens directly to DCs in vivo is an alternative and simpler strategy. The identification of cell surface receptors on DCs, and targeting antigens to DC receptors, has become a popular approach for inducing effective immune responses against cancer antigens. Many years ago, we demonstrated that targeting the mannose receptor on macrophages using the carbohydrate mannan to DCs led to appropriate immune responses and tumour protection in animal models. We conducted Phase I, I/II and II, clinical trials demonstrating the effectiveness of oxidised mannan-MUC1 in patients with adenocarcinomas. Here we summarise DC targeting approaches and their efficacy in human clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=84947267445&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84947267445&partnerID=8YFLogxK
U2 - 10.1038/cti.2014.14
DO - 10.1038/cti.2014.14
M3 - Review article
AN - SCOPUS:84947267445
SN - 2050-0068
VL - 3
JO - Clinical and Translational Immunology
JF - Clinical and Translational Immunology
IS - 7
M1 - e21
ER -